Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO

publication date: Sep 13, 2019

Zhejiang Jiuzhou Pharma, an API company, will pay $16 million to acquire PharmAgra Labs of North Carolina, a small API CRO/CDMO business with contacts in the US and Europe. Jiuzhou makes APIs and it also provides CRO/CDMO services for APIs in China through its Rainbow Pharma division. In 2016, Jiuzhou formed a US JV with Frontage Labs to offer API and intermediate CDMO services. Earlier this month, Jiuzhou announced it would pay $110 million to acquire Novartis's Suzhou API facility and supply APIs to Novartis. More details....

Stock Symbols: (SHA: 603456) (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital